Kamada (KMDA)

• Market cap: $387M
• 1 day: 0.30%
• 5 days: -3.03%
• 1 month: 10.51%
• 3 months: 17.25%
• 6 months: 19.12%
• Year to date: 6.32%
• 1 year: 17.45%
• 5 years: 3.54%
• 10 years: 64.55%

About: Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Employees: 378

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

6% more capital invested

Capital invested by funds: $32.7M [Q2] → $34.8M (+$2.04M) [Q3]

0% more funds holding

Funds holding: 30 [Q2] → 30 (+0) [Q3]

0.19% less ownership

Funds ownership: 11.45% [Q2] → 11.26% (-0.19%) [Q3]

30% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 10

99% less call options, than puts

Call options by funds: $2K | Put options by funds: $139K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $11 63% upside
• Avg. target: $11 63% upside
• High target: $11 63% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Andrew Fein 37% 1-year accuracy 127 / 343 met price target

63% upside $11

Buy Reiterated

10 Jan 2025